Affymax Promotes Michael Holfinger, Ph.D., to Vice President, Manufacturing and CMC Development
PALO ALTO, Calif.--(BUSINESS WIRE)--
Affymax, Inc. (Nasdaq: AFFY) today announced the promotion of Michael
Holfinger, Ph.D., to vice president, manufacturing and CMC development.
Dr. Holfinger, who has more than two decades of experience in global
manufacturing services for pharmaceutical and biotechnology companies,
joined Affymax in 2006 as director, process development and
"During his tenure at Affymax, Mike has shown impressive leadership
skills and made significant contributions to our process and
manufacturing development program for OMONTYS," said John Orwin, chief
executive officer of Affymax. "Looking ahead, his proven track record of
overseeing complex commercial production at a global level and his
intimate familiarity with the manufacturing process we have developed
with our partner, Takeda, will be essential as we increase commercial
Prior to joining Affymax, Dr. Holfinger held multiple positions at
Pfizer, including most recently as senior manager in the API support
team where he was responsible for change management, project management
and technical support activities necessary to ensure an economical
uninterrupted commercial supply of pharmaceutical ingredients for
various products. Prior to Pfizer, Dr. Holfinger held multiple positions
within the chemical process research and development group at Pharmacia
Corporation, where he was responsible for implementation of commercial
processes for the manufacturing of chemical intermediates and active
pharmaceutical ingredients. From 1997-2004, he was a course instructor
at the Pharmaceutical Education & Research Institute. He earned his
Ph.D. in chemical engineering from the University of Wisconsin-Madison
and received a dual B.S. degree in applied science, paper science, and
engineering and chemistry at Miami University.
About Affymax, Inc.
Affymax, Inc. is a biopharmaceutical company based in Palo Alto,
California. Affymax's mission is to discover, develop and deliver
innovative therapies that improve the lives of patients with kidney
disease and other serious and often life-threatening illnesses.
The company's first marketed product, OMONTYS® (peginesatide) Injection,
was approved by the U.S. Food and Drug Administration (FDA) in March
2012. For additional information, please visit www.affymax.com.
Alexandra Santos, 650-812-8961
Director, Corporate Communications
Source: Affymax, Inc.
News Provided by Acquire Media
Close window | Back to top